CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies

Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/β-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways

(2015) Lu Zhou et al.   NEOPLASIA

Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria

(2013) Scott R. Plotkin et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells

(2013) Robin D. S. Doddrell et al.   BRAIN

Calvarial defects and skeletal dysplasia in patients with neurofibromatosis Type 1

(2013) Daniel K. Arrington et al.   Journal of Neurosurgery-Pediatrics

Merlin isoform 2 in neurofibromatosis type 2–associated polyneuropathy

(2013) Alexander Schulz et al.   NATURE NEUROSCIENCE

Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target

(2012) A. V. Patel et al.   CLINICAL CANCER RESEARCH

The Tumor Suppressor Merlin Controls Growth in Its Open State, and Phosphorylation Converts It to a Less-Active More-Closed State

(2012) Ifat Sher et al.   DEVELOPMENTAL CELL

Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1

(2012) KARIN S WALSH et al.   DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: a new syndrome

(2012) D Babovic-Vuksanovic et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Merlin/ERM proteins establish cortical asymmetry and centrosome position

(2012) A. M. Hebert et al.   GENES & DEVELOPMENT

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

(2012) Y. Liu-Chittenden et al.   GENES & DEVELOPMENT

A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1

(2012) I. B. Stowe et al.   GENES & DEVELOPMENT

Expression of SMARCB1 (INI1) mutations in familial schwannomatosis

(2012) M. J. Smith et al.   HUMAN MOLECULAR GENETICS

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

(2012) Walter J. Jessen et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-term natural history of neurofibromatosis Type 2–associated intracranial tumors

(2012) Michael S. Dirks et al.   JOURNAL OF NEUROSURGERY

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial

(2012) Kent A Robertson et al.   LANCET ONCOLOGY

Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types

(2012) M. F. James et al.   MOLECULAR CANCER RESEARCH

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila

(2012) Michael C. Wehr et al.   NATURE CELL BIOLOGY

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas

(2012) Matthias A. Karajannis et al.   NEURO-ONCOLOGY

Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis

(2012) M. J. Fisher et al.   NEURO-ONCOLOGY

Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis

(2012) Miriam J. Smith et al.   NEUROGENETICS

A Radial Glia-Specific Role of RhoA in Double Cortex Formation

(2012) Silvia Cappello et al.   NEURON

c-Jun Reprograms Schwann Cells of Injured Nerves to Generate a Repair Cell Essential for Regeneration

(2012) Peter J. Arthur-Farraj et al.   NEURON

Lovastatin regulates brain spontaneous low-frequency brain activity in Neurofibromatosis type 1

(2012) Camille Chabernaud et al.   NEUROSCIENCE LETTERS

The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38SAPK pathway

(2012) R F Hennigan et al.   ONCOGENE

Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients

(2012) V. L. Merker et al.   ONCOLOGIST

Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis

(2012) Scott R. Plotkin et al.   PLoS One

Mechanisms of Hearing Loss in Neurofibromatosis Type 2

(2012) Ashok R. Asthagiri et al.   PLoS One

Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis

(2011) Miriam J. Smith et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia

(2011) Mignon L. Loh   BRITISH JOURNAL OF HAEMATOLOGY

A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin's Regulation of Mitogenic Signaling and Tumor Suppressive Functions

(2011) Chunling Yi et al.   CANCER CELL

Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors

(2011) Thomas De Raedt et al.   CANCER CELL

Aurora A Is a Repressed Effector Target of the Chromatin Remodeling Protein INI1/hSNF5 Required for Rhabdoid Tumor Cell Survival

(2011) S. Lee et al.   CANCER RESEARCH

BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma

(2011) C. Hawkins et al.   CLINICAL CANCER RESEARCH

Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas

(2011) K. Jacob et al.   CLINICAL CANCER RESEARCH

PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice

(2011) Jacquelyn A. Brown et al.   EXPERIMENTAL NEUROLOGY

Empirical development of improved diagnostic criteria for neurofibromatosis 2

(2011) Michael E Baser et al.   GENETICS IN MEDICINE

Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas

(2011) Abraham Jacob et al.   LARYNGOSCOPE

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas

(2011) M. L. Bush et al.   NEURO-ONCOLOGY

Tumor suppression by cell competition through regulation of the Hippo pathway

(2011) C.-L. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice

(2011) N. Lyubynska et al.   Science Translational Medicine

Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus

(2010) Wei Li et al.   CELL

Glucocorticoids Suppress Bone Formation by Attenuating Osteoblast Differentiation via the Monomeric Glucocorticoid Receptor

(2010) Alexander Rauch et al.   Cell Metabolism

Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice

(2010) Jacquelyn A. Brown et al.   HUMAN MOLECULAR GENETICS

Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas

(2010) I. Christiaans et al.   JOURNAL OF MEDICAL GENETICS

SMARCB1 mutations are not a common cause of multiple meningiomas

(2010) K. D. Hadfield et al.   JOURNAL OF MEDICAL GENETICS

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma

(2010) S. Ammoun et al.   NEURO-ONCOLOGY

Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1

(2010) M. E. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis

(2009) C Boyd et al.   CLINICAL GENETICS

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244

(2009) Sylwia Ammoun et al.   NEUROBIOLOGY OF DISEASE

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

(2009) Scott R. Plotkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Burden in Patients with Neurofibromatosis Types 1 and 2 and Schwannomatosis: Determination on Whole-Body MR Images

(2009) Wenli Cai et al.   RADIOLOGY

Dissecting and Targeting the Growth Factor-Dependent and Growth Factor-Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma

(2008) S. Ammoun et al.   CANCER RESEARCH

Pam (Protein associated with Myc) functions as an E3 Ubiquitin ligase and regulates TSC/mTOR signaling

(2008) Sangyeul Han et al.   CELLULAR SIGNALLING

TORC1 Is Essential for NF1-Associated Malignancies

(2008) Cory M. Johannessen et al.   CURRENT BIOLOGY

Evidence of a four-hit mechanism involvingSMARCB1andNF2in schwannomatosis-associated schwannomas

(2007) Roberta Sestini et al.   HUMAN MUTATION